US EditionPublished • loading... • Updated
Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
- Akeso, Inc. received clearance from China's National Medical Products Administration to start Phase II clinical trials for two novel antibody-drug conjugates, AK146D1 and AK138D1, targeting cancer antigens Trop2/Nectin4 and HER3 respectively.
- The trials will study these antibody-drug conjugates combined with Akeso's bispecific antibodies cadonilimab and ivonescimab, along with other anti-tumor agents, across various advanced solid tumors.
- Advancing 'IO 2.0 + ADC 2.0' combinations into Phase II marks a key step in Akeso's progress toward next-generation leadership in global oncology.
- AK146D1 targets Trop2 and Nectin4 antigens found in certain cancers, while AK138D1 targets HER3, which is associated with tumor growth and treatment resistance.
Insights by Ground AI
45 Articles
45 Articles
Akeso Advances 'IO 2.0 + ADC 2.0' Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
HONG KONG, March 25, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced today that it has received clearance from the Center for Drug Evaluation...
·Manila, Philippines (the)
Read Full Article
The Berkshire Eagle+43 Reposted by 43 other sources
Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical…
Coverage Details
Total News Sources45
Leaning Left3Leaning Right5Center19Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
11%
C 70%
R 19%
Factuality
To view factuality data please Upgrade to Premium
